{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:15:51Z","timestamp":1779369351059,"version":"3.53.0"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1010797","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000}}],"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005195","name":"Office of Public Health Preparedness and Response","doi-asserted-by":"publisher","award":["75A50121C00023"],"award-info":[{"award-number":["75A50121C00023"]}],"id":[{"id":"10.13039\/100005195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600017I"],"award-info":[{"award-number":["HHSO100201600017I"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>To aid understanding of the effect of antiviral treatment on population-level influenza transmission, we used a novel pharmacokinetic\u2013viral kinetic transmission model to test the correlation between nasal viral load and infectiousness, and to evaluate the impact that timing of treatment with the antivirals oseltamivir or baloxavir has on influenza transmission. The model was run under three candidate profiles whereby infectiousness was assumed to be proportional to viral titer on a natural-scale, log-scale, or dose\u2013response model. Viral kinetic profiles in the presence and absence of antiviral treatment were compared for each individual (N = 1000 simulated individuals); subsequently, viral transmission mitigation was calculated. The predicted transmission mitigation was greater with earlier administration of antiviral treatment, and with baloxavir versus oseltamivir. When treatment was initiated 12\u201324 hours post symptom onset, the predicted transmission mitigation was 39.9\u201356.4% for baloxavir and 26.6\u201338.3% for oseltamivir depending on the infectiousness profile. When treatment was initiated 36\u201348 hours post symptom onset, the predicted transmission mitigation decreased to 0.8\u201328.3% for baloxavir and 0.8\u201319.9% for oseltamivir. Model estimates were compared with clinical data from the BLOCKSTONE post-exposure prophylaxis study, which indicated the log-scale model for infectiousness best fit the observed data and that baloxavir affords greater reductions in secondary case rates compared with neuraminidase inhibitors. These findings suggest a role for baloxavir and oseltamivir in reducing influenza transmission when treatment is initiated within 48 hours of symptom onset in the index patient.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1010797","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:53:27Z","timestamp":1673031207000},"page":"e1010797","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel modelling approaches to predict the role of antivirals in reducing influenza transmission"],"prefix":"10.1371","volume":"19","author":[{"given":"Jason","family":"Asher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-8188","authenticated-orcid":true,"given":"Annabelle","family":"Lemenuel-Diot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8791-366X","authenticated-orcid":true,"given":"Matthew","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-4541","authenticated-orcid":true,"given":"Luis","family":"Mier-y-Teran-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos J.","family":"Arguello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Jolivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kuhlbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Clinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Eric","family":"Charoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"issue":"1","key":"pcbi.1010797.ref001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(18)30496-X","article-title":"Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017","volume":"7","author":"CE Troeger","year":"2019","journal-title":"The Lancet Respiratory Medicine"},{"key":"pcbi.1010797.ref002","article-title":"United States Centers for Disease Control and Prevention","journal-title":"Disease Burden of Flu 2022"},{"issue":"10","key":"pcbi.1010797.ref003","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"FG Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"pcbi.1010797.ref004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijid.2019.08.028","article-title":"Epidemiological features and trends of influenza incidence in mainland China: A population-based surveillance study from 2005 to 2015","volume":"89","author":"S Sun","year":"2019","journal-title":"International Journal of Infectious Diseases"},{"issue":"10","key":"pcbi.1010797.ref005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"MG Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pcbi.1010797.ref006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/dkg007","article-title":"Early administration of oral oseltamivir increases the benefits of influenza treatment","volume":"51","author":"FY Aoki","year":"2003","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"8","key":"pcbi.1010797.ref007","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial","volume":"283","author":"JJ Treanor","year":"2000","journal-title":"JAMA"},{"key":"pcbi.1010797.ref008","author":"AG Roche Pharma","year":"2020","journal-title":"Tamiflu Summary of Product Characteristics (SmPC)"},{"issue":"3","key":"pcbi.1010797.ref009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/AAC.42.3.647","article-title":"Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071","volume":"42","author":"W Li","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1010797.ref010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"T Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"pcbi.1010797.ref011","author":"Genentech USA Inc","year":"2019","journal-title":"Highlights of prescribing information: XOFLUZA (baloxavir marboxil) tablets, for oral use"},{"issue":"8","key":"pcbi.1010797.ref012","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)","volume":"39","author":"J Baker","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"pcbi.1010797.ref013","author":"D Kumar","year":"2020"},{"issue":"4","key":"pcbi.1010797.ref014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts","volume":"383","author":"H Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"pcbi.1010797.ref015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: a review of volunteer challenge studies","volume":"167","author":"F Carrat","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pcbi.1010797.ref016","doi-asserted-by":"crossref","first-page":"e1000656","DOI":"10.1371\/journal.pcbi.1000656","article-title":"FluTE, a publicly available stochastic influenza epidemic simulation model","volume":"6","author":"DL Chao","year":"2010","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"pcbi.1010797.ref017","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41591-020-0843-2","article-title":"Respiratory virus shedding in exhaled breath and efficacy of face masks","volume":"26","author":"NHL Leung","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"pcbi.1010797.ref018","doi-asserted-by":"crossref","first-page":"e1003205","DOI":"10.1371\/journal.ppat.1003205","article-title":"Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks","volume":"9","author":"DK Milton","year":"2013","journal-title":"PLoS Pathog"},{"issue":"5","key":"pcbi.1010797.ref019","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1073\/pnas.1716561115","article-title":"Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community","volume":"115","author":"J Yan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"pcbi.1010797.ref020","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/infdis\/jiv225","article-title":"Influenza A Virus Shedding and Infectivity in Households","volume":"212","author":"TK Tsang","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"pcbi.1010797.ref021","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1038\/s41467-020-16585-y","article-title":"Modeling mitigation of influenza epidemics by baloxavir","volume":"11","author":"Z Du","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1010797.ref022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10928-010-9175-z","article-title":"The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects","volume":"38","author":"PL Chan","year":"2011","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"pcbi.1010797.ref023","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1128\/AAC.00069-15","article-title":"A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression","volume":"59","author":"MA Kamal","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"pcbi.1010797.ref024","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"J Virol"},{"key":"pcbi.1010797.ref025","unstructured":"FDA Review and Evaluation. NDA 210854. Xofluza (baloxavir marboxil) 2018 [cited 2022 12 October]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210854Orig1s000TOC.cfm."}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1010797","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T18:42:53Z","timestamp":1674672173000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010797"}},"subtitle":[],"editor":[{"given":"Benjamin","family":"Althouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1010797","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1010797","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]}}}